Dickerson ED: The 20 essential drugs in palliative care. European Journal of Palliative Care. 1999; 6(4): 130-135.
2.
Collins SL, Moore RA, McQuay HJ, et al.: Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: A quantitative systematic review. Journal of Pain and Symptom Management. 2000; 20(6): 449-458
3.
Breitbart W, Jaramillo JR, Chochinov HM: Palliative and terminal Care. In Holland JC (ed.): Psycho-oncology. Oxford: Oxford University Press, 1998, 437-449.
4.
Spiegel L: Pediatric psychopharmacology. In Holland JC (ed.): Psycho-oncology. Oxford: Oxford University Press. 1998; 954-961.
5.
Kent JM: SnaRIs, NaSSAS, and NaRIs: New agents for the treatment of depression. Lancet. 2000; 355: 911-918.
6.
de Boer TH: The pharmacologic profile of mirtazapine. Journal of Clinical Psychiatry. 1996; 57: 19-25.
7.
Davis MP, Dickerson ED, Pappagallo M, et al.: Mirtazapine: Heir apparent to amitriptyline?American Journal of Hospice and Palliative Care. 2000; 18(1): 1-5.
8.
Fulton B, Goa KL: Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997; 53(2): 281-298.
9.
Kando JC, Shepski JC, Satterlee W, et al.: Olanzapine: A new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother. 1997; 31(11): 1325-1334.
10.
Bever KA, Perry RJ: Olanzapine: A serotonin-dopamine-receptor antagonist for antipsychotic therapy. Am J Heath Syst Pharm. 1998; 55(10): 1003-1016.
11.
Bigliani V, Mulligan RS, Acton PD, et al.: Striatal and temporal cortical D23/D3 receptor occupancy by olanzapine and sertindole in vivo: A [123I] epidepride single photon emission tomography (SPET) study. Psychopharmacology. 2000; 150(2): 132-140.
12.
Conley RR, Meltzer HY: Adverse events related to olanzapine. J Clin Psychiatry. 2000; 61(suppl 8): 26-29.
13.
Green B: Focus on olanzapine. Curr Med Res Opin. 1999; 15(2): 79-85.
14.
Markowitz JS, Brown CS, Moore TR: Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother. 1999; 33(1): 73-85.
15.
Worrel JA, Marken PA, Beckman SE, et al.: Atypical antipsychotic agents: A critical review. Am J Health Syst Pharm. 2000; 57(3): 238-255.
16.
Stephenson CME, Pilowsky LS: Psychopharmacology of olanzapine: A review. The British Journal of Psychiatry. 1999; 174 (38S): 52-58.
17.
Callaghan JT, Bergstrom RF, Ptak LR, et al.: Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharamcokinet. 1999; 37(3); 177-193.
18.
Olesen OV, Linnet K: Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication. Ther Drug Monit. 1999; 21(1); 87-90.
Beasley CM Jr, Hamilton SH, Crawford AM, et al.: Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997; 7(2); 125-137.
21.
Madhusoodanan S, Brenner R, Suresh P, et al.: Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: A prospective study. Ann Clin Psychiatry. 2000; 12(1); 11-18.
22.
Allan ER, Sison CE, Alpert M, et al.: The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine. Psychopharmacol Bull. 1998; 34(1): 71-74.
23.
McElroy SL, Frye M, Denicoff K, et al.: Olanzapine in treatment-resistant bipolar disorder. J Affect Disord. 1998; 49(2): 119-122.
24.
Stanfield SC, Privette T: Neuroleptic malignant syndrome associated with olanzapine therapy: A case report. J Emerg Med. 2000; 19(4); 355-357.
25.
Rothschild AJ, Bates KS, Boehringer KL, et al.: Olanzapine response in psychotic depression. J Clin Psychiatry. 1999; 60(2): 116-118.
26.
Zarate CA, Narendran R, Tohen M, et al.: Clinical predictors of acute response with olanzapine in psychotic mood. J Clin Psychiatry. 1998; 59(1): 24-28.
27.
Hamilton SH, Revicki DA, Genduso LA, et al.: Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neurophsycopharmacology. 1998; 18(1): 41-49.
28.
Jarventuasta K, Leinonen E: Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. Acta Psychiatr Scand. 2000; 102(3); 231-233.
29.
Tran PV, Hamilton SH, Kuntz AJ, et al.Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997; 17(5), 407-418.
30.
Beasley CM Jr, Tollefson GD, Tran PV: Safety of olanzapine. J Clin Psychiatry. 1997; 58(suppl 10): 13-17.
31.
Leucht S, Pitschel-Walz G, Abraham D, et al.: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999; 35(1): 51-68.
32.
Beasley CM Jr, Tollefson GD, Tran P, et al.: Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996; 14(2): 111-123.
33.
Foster RH, Goa KL: Olanzapine. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics. 1999; 15(6), 611-640.
34.
Lucas RA, Gilfillan DJ, Bergstrom RF: A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanism. Eur J Clin Pharmacol. 1998; 54(8); 639-643.
